Applications of nanovesicular drug delivery

Detalles Bibliográficos
Clasificación:Libro Electrónico
Otros Autores: Nayak, Amit Kumar
Formato: Electrónico eBook
Idioma:Inglés
Publicado: London : Academic Press, 2022.
Temas:
Drug delivery systems.
Nanomedicine.
Drug Delivery Systems
Nanomedicine
Syst�emes d'administration de m�edicaments.
Nanom�edecine.
Drug delivery systems
Acceso en línea:Texto completo
Tabla de Contenidos:
  • Front Cover
  • Applications of Nanovesicular Drug Delivery
  • Copyright Page
  • Contents
  • List of contributors
  • Preface
  • 1 Targeting cellular and molecular mechanisms of nanovesicular systems for the treatment of different diseases
  • 1.1 Introduction
  • 1.2 Lipid nanovesicular systems
  • 1.2.1 Liposomes
  • 1.2.2 Elastic liposomes: ethosomes and transferosomes
  • 1.2.3 Niosomes
  • 1.2.4 Ufasomes
  • 1.3 Polymer nanovesicular systems
  • 1.3.1 Polymersomes/polymer vesicles
  • 1.3.2 Nanovesicular systems for targeting to cellular mechanisms
  • 1.3.3 Nanovesicular systems for targeting molecular mechanisms and the era of CRISPR/CAS9
  • 1.3.4 Nanovesicular systems for the treatment of different diseases
  • 1.4 Conclusions
  • References
  • 2 Nanovesicles for drug codelivery
  • 2.1 Introduction
  • 2.2 Combination drug therapy
  • 2.3 General overview of nanovesicles
  • 2.3.1 Liposomes
  • 2.3.2 Niosomes
  • 2.3.3 Exosomes
  • 2.3.4 Spanlastics
  • 2.4 Design and preparation techniques of codelivery nanovesicles
  • 2.4.1 Mechanical dispersion/film hydration method
  • 2.4.2 Ultrasonication method
  • 2.4.3 Self-assembling
  • 2.4.4 Solvent dispersion methods
  • 2.4.5 Detergent removal method
  • 2.4.6 Microfluidization method
  • 2.4.7 Handjani-Vila method
  • 2.5 Nanodrug codelivery systems
  • 2.5.1 Nanovesicles-hydrogels for codelivery of drugs
  • 2.5.2 Nanovesicles for codelivery of anticancer drugs
  • 2.5.3 Nanovesicles for codelivery of cardiovascular drugs
  • 2.5.4 Nanovesicles for codelivery of antibacterial/antiinflammatory drugs
  • 2.6 Conclusion
  • References
  • 3 Theranostic nanovesicles
  • 3.1 Introduction
  • 3.2 Imaging strategies
  • 3.2.1 Optical imaging
  • 3.2.2 Magnetic resonance imaging
  • 3.2.3 Radionuclide-based imaging
  • 3.2.4 Computed tomography
  • 3.2.5 Ultrasound
  • 3.3 Different nanovesicles used as theranostic system.
  • 3.3.1 Liposomes
  • 3.3.2 Ethosomes
  • 3.3.3 Transferosomes
  • 3.3.4 Niosomes
  • 3.3.5 Polymersomes
  • 3.4 Conclusion
  • References
  • 4 Nanovesicles for ocular drug delivery
  • 4.1 Introduction
  • 4.2 Physiology, routes of drug administration and ocular barriers for drug penetration
  • 4.2.1 Physiology of the eye
  • 4.2.2 Routes of drug administration to the eye and corresponding ocular barriers
  • 4.3 Ocular diseases
  • 4.3.1 Anterior segment diseases
  • 4.3.2 Posterior segment diseases
  • 4.4 Nanovesicles for ocular drug delivery
  • 4.4.1 Preclinical studies
  • 4.4.1.1 Nanovesicles for anterior segment disease treatment
  • 4.4.1.2 Nanovesicles for posterior segment disease treatment
  • 4.4.1.3 Nanovesicle assisted gene therapy for ocular disease treatment
  • 4.4.2 Clinical studies and approved products
  • 4.5 Conclusions and future perspectives
  • Acknowledgments and funding
  • References
  • 5 Nanovesicles for nasal drug delivery
  • 5.1 Introduction
  • 5.2 Intranasal drug delivery system
  • 5.3 Dosage forms and absorption enhancers
  • 5.3.1 Nasal drops
  • 5.3.2 Nasal spray
  • 5.3.3 Nasal gel
  • 5.3.4 Nasal powders
  • 5.4 Benefits of intranasal drug delivery
  • 5.5 Barriers in nasal distribution
  • 5.5.1 Poor bioavailability
  • 5.5.2 Biliary clearance
  • 5.5.3 Enzyme degradation
  • 5.6 Need for intranasal drug delivery system
  • 5.7 Anatomy and physiology of nasal route
  • 5.8 Mechanism of absorption of drugs via nasal route
  • 5.8.1 Intracellular pathway
  • 5.8.2 Transcellular transport
  • 5.9 Nasal devices
  • 5.10 Role of nanotechnology intranasal drug delivery
  • 5.11 Nanovesicles for intranasal drug delivery
  • 5.11.1 Lipid based nanovesicles
  • 5.11.1.1 Liposomes
  • 5.11.1.1.1 Method of preparation of liposomes
  • 5.11.1.2 Transfersomes
  • 5.11.1.2.1 Method of preparation of transfersomes
  • 5.11.1.3 Ethosomes.
  • 5.11.1.3.1 Method of preparation of ethosomes
  • 5.11.1.4 Magnesomes
  • 5.11.1.4.1 Method of preparation of magnesomes
  • 5.11.1.5 Ufasome
  • 5.11.1.5.1 Method of preparation of ufasomes
  • 5.11.1.6 Novasomes
  • 5.11.1.6.1 Method of preparation of novasomes
  • 5.11.2 Nonionic surfactant based nanovesicles
  • 5.11.2.1 Niosomes
  • 5.11.2.1.1 Method of preparation of niosomes
  • 5.11.2.2 Spanlastics
  • 5.11.2.2.1 Method of Preparation of spanlastics
  • 5.11.3 Biologically derived nanovesicles
  • 5.11.3.1 Exosomes
  • 5.11.3.1.1 Method of preparation of exosomes
  • 5.12 Applications of nanovesicular intranasal delivery system
  • 5.12.1 Viral infection
  • 5.12.2 Osteoclastic bone resorption
  • 5.12.3 Central nervous system disorders
  • 5.12.4 Migraine
  • 5.12.5 Hypertension
  • 5.12.6 Anxiety disorders
  • 5.12.7 Antinociceptive
  • 5.12.8 Oxytocin and insulin delivery
  • 5.12.9 Cancer
  • 5.12.10 Neurodegenerative/brain inflammatory disease
  • 5.12.11 Cerebral arteriosclerosis, thrombosis, and vertigo disorders
  • 5.13 Conclusion
  • References
  • 6 Nanovesicles for transdermal drug delivery
  • 6.1 Introduction
  • 6.1.1 The mechanisms of interactions between nanovesicle systems and skin
  • 6.2 Lipid-based vesicular nanostructures for transdermal drug delivery
  • 6.2.1 Traditional liposomes as skin drug delivery systems
  • 6.2.2 Transfersomes
  • 6.2.3 Ethosomes
  • 6.2.4 Invasome
  • 6.2.5 Glycerosomes
  • 6.2.6 Hyalurosomes
  • 6.3 Nanovesicles formed by nonlipid building blocks
  • 6.3.1 Niosomes as transdermal drug delivery systems
  • 6.3.2 Polymersomes as transdermal drug delivery systems
  • 6.4 Conclusion and future perspective
  • References
  • 7 Nanovesicles for intravenous drug delivery
  • 7.1 Introduction
  • 7.2 Intravenous drug administration
  • 7.3 Nanovesicular systems
  • 7.3.1 Liposomes
  • 7.3.2 Niosomes
  • 7.3.3 Polymersomes
  • 7.3.4 Transfersomes.
  • 7.3.5 Ethosomes and ethosomal nanovesicles
  • 7.3.6 Phytosomes
  • 7.3.7 Extracellular vesicles
  • 7.4 Intravenous nanovesicles for imaging
  • 7.5 Intraveneous nanovesicles for therapy
  • 7.5.1 Tumor targeting and cancer therapy
  • 7.5.2 Fungal infections
  • 7.5.3 Pain management and inflammatory diseases
  • 7.5.4 Others
  • 7.6 Intravenous nanovesicles for gene therapy
  • 7.6.1 Intravenous nanovesicular systems developed for gene augmentation
  • 7.6.2 Intravenous nanovesicular systems developed for gene silencing (suppression)
  • 7.6.3 Intravenous nanovesicular systems developed for genome editing
  • 7.7 Intravenous nanovesicles for theranostic
  • 7.8 Conclusion
  • References
  • 8 Nanovesicles for target specific drug delivery
  • 8.1 Introduction
  • 8.2 Liposomes as drug delivery vesicles
  • 8.2.1 Types of liposomes
  • 8.2.2 Applications
  • 8.3 Polymeric micelles as drug delivery vehicles
  • 8.3.1 Applications
  • 8.4 Exosomes as drug delivery vesicles
  • 8.4.1 Applications
  • 8.5 Niosomes-drug delivery vesicles
  • 8.5.1 Applications
  • 8.6 New era of vesicular drug delivery systems
  • 8.6.1 Transferosomes
  • 8.6.2 Ethosomes
  • 8.6.3 Sphingosomes
  • 8.6.4 Cubosomes
  • 8.6.5 Ufasomes
  • 8.6.6 Colloidosomes
  • 8.6.7 Aquasomes
  • 8.6.8 Polymerosomes
  • 8.6.9 Emulsomes
  • 8.6.10 Virosomes
  • 8.6.11 Enzymosomes
  • 8.6.12 Pharmacosomes
  • 8.7 Conclusions
  • References
  • 9 Blood-brain barrier and nanovesicles for brain-targeting drug delivery
  • 9.1 Introduction
  • 9.2 Neurovascular unit
  • 9.2.1 Blood-brain barrier and blood-cerebrospinal fluid barrier roles
  • 9.2.2 Immunosurveillance in neurovascular unit
  • 9.2.3 Tight junctional molecular machinery
  • 9.2.4 Blood-brain barrier models
  • 9.2.5 Blood-brain barrier transport machinery
  • 9.2.6 Endocytosis, transcytosis, and vesicular trafficking
  • 9.2.7 Nanovesicles delivery mechanisms.

Ejemplares similares